Is Amylyx Pharmaceuticals, Inc. (AMLX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 11.6% / 30% | 0.0% / 30% | 15.81% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 11.6% / 33% | 0.0% / 33% | 15.81% / 5% | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 91.2% / 33% | 0.2% / 33% | 15.81% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 11.6% / 33% | 0.0% / 33% | 15.81% / 5% | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 91.2% / 33% | 0.2% / 50% | 15.81% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -61.6% | |
| Return on Assets (ROA) | -36.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$123M |
| Free Cash Flow | -$123M |
| Total Debt | $6M |
| Debt-to-Equity | 2.0 |
| Current Ratio | 14.3 |
| Total Assets | $333M |
Price & Trading
| Last Close | $13.47 |
| 50-Day MA | $14.44 |
| 200-Day MA | $11.89 |
| Avg Volume | 1.3M |
| Beta | -0.3 |
|
52-Week Range
$3.11
| |
About Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Amylyx Pharmaceuticals, Inc. (AMLX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Amylyx Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Amylyx Pharmaceuticals, Inc.'s debt ratio?
Amylyx Pharmaceuticals, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Amylyx Pharmaceuticals, Inc.'s key financial metrics?
Amylyx Pharmaceuticals, Inc. has a market capitalization of $1.5B. Return on equity stands at -61.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.